183 related articles for article (PubMed ID: 21420283)
1. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
3. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM
Neuropsychopharmacology; 2010 Jan; 35(2):581-90. PubMed ID: 19890258
[TBL] [Abstract][Full Text] [Related]
4. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
[TBL] [Abstract][Full Text] [Related]
5. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
[TBL] [Abstract][Full Text] [Related]
6. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
8. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
9. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
[TBL] [Abstract][Full Text] [Related]
10. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Mozes T; Ebert T; Michal SE; Spivak B; Weizman A
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):393-403. PubMed ID: 16958565
[TBL] [Abstract][Full Text] [Related]
11. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
13. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
14. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.
Brousse G; Meary A; Blanc O; Lançon C; Llorca PM; Leboyer M
Psychiatry Res; 2010 Aug; 179(1):12-8. PubMed ID: 20472305
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
[TBL] [Abstract][Full Text] [Related]
18. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
19. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
